Markets

FDA Provides Fast Track Designation SAB Biotherapeutics' SAB-142 To Treat Stage 3 Type 1 Diabetes

Oct 13, 2026 · 08:34 AM ET· updated 1h ago

SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced

Why It Matters

The FDA gave SAB Biotherapeutics' diabetes medicine a fast track label. This means the FDA thinks it could help patients and will review it quicker than normal.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

SABS2.80

-0.03 (-1.06%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.